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SUMMARY
1 Perceptions of risks from prescription drugs are likely to
influence patients' treatment choices, their compliance with
treatment regimens, their views on the acceptability of
adverse reactions, and their attitudes towards government
regulation of medicines.
2 Understanding perceptions of drug risks is a prerequisite
for designing better communication materials for patients and
the public.
3 This article presents the results of a survey that
examined the attitudes and perceptions of a representative
sample of the Swedish adult population during February and
March, 1988.
4 Respondents characterized themselves as persons who
disliked taking risks and who resisted taking medicines
unless forced to do so. They were also concerned about
chemicals, perceiving substances such as food additives and
pesticides to be very high in risk and low in benefit.
5 Prescription drugs, with the exception of sleeping pills
and antidepressants, were perceived to be high in benefit and
low in risk. They appeared to be sharply differentiated from
other chemicals and from illicit drugs.
6 High perceived risks associated with sleeping pills and
antidepressants seem to be derived from concerns about
overdose, addiction, and abuse.
7 Evidence for safety and efficacy, in combination with
warning information, appeared to make people much more
tolerant of the risks for a drug suspected of causing fatal
reactions in some patients.
8 Replication of this type of survey in other countries and
with patients as well as the general public would help
pharmaceutical companies understand the influence of
perceptions on the sociopolitical environment in which they
must operate.
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INTRODUCTION
Knowledge of perception has been demonstrated to be vitally
important in understanding how individuals and societies manage
the risks of daily life. ' In medicine, perceptions of drug
risks are likely to influence patients' treatment choices, their
compliance with treatment regimens, their views on the
acceptability of adverse reactions, and their attitudes toward
3government regulation of drugs. Understanding perceptions is
a prerequisite for designing better communication materials for
patients and the public. Yet most work on perception of risk has
focused on nuclear power, industrial chemicals, and other
nonmedical hazards. Few, if any, studies have examined
perceptions of pharmaceutical risks. The present study attempts
to remedy this deficiency. It reports the first of a series of
surveys designed to do the following:
1. Describe precisely and quantitatively the public's
perceptions of risk and benefit from the use of various kinds of
prescription drugs.
2. Place perceptions of prescription drugs within a broader
context of risk perceptions regarding many other activities (e.g.,
driving, smoking) and technologies (e.g., air travel,
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pesticides), including other medical technologies (X rays,
surgery).
3. Allow comparisons to be made across populations from
different nations and, within national samples, across important
personal and demographic characteristics (e.g., health status,
age).
4. Provide baseline data that will allow the impact of new drug
problems and controversies to be monitored and allow trends in
relevant attitudes and perceptions to be followed over time.
5. Contribute to basic knowledge and understanding of the
influence of public perceptions on the sociopolitical environment
in which pharmaceutical companies operate.
The data presented in this paper come from a survey that
examined the attitudes and perceptions of a representative sample
of the adult population of Sweden during February and March, 1988.
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DESIGN AND ADMINISTRATION OF THE SURVEY
Part I: General Attitudinal and Demographic Questionnaire
The survey had two separate components. Part I employed a
traditional survey format in which respondents are asked to
indicate their attitudes, perceptions, and opinions in response to
specific questions. In addition, Part I included a nontraditional
task in which respondents were asked to read the words
'prescription drugs' which were printed six times on a card. Each
time they read these words, they were instructed to write down the
first association that came to their minds. This technique,
called 'the method of continued associations,' has been shown by
Szalay and Deese^ to be a sensitive indicator of the imagery
and meaning associated with people's mental representations for a
wide variety of concepts. Of particular interest in the present
context is the frequency and nature of negative associations and
the ratio of positive to negative responses.
In addition to the imagery task, other questions in Part I
asked about the following:
• Perceptions of risk today as compared to risks in the past.
• Perceived frequency of side effects.
• The adequacy of performance by government regulators, drug
manufacturers, doctors, and pharmacists in ensuring drug
safety and efficacy.
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• The respondent's personal experiences with drug side effects.
• Perceived causes of side effects.
• Opinions in response to a vignette describing a drug controversy.
Part I concluded with a series of demographic questions
pertaining to the patient's age, sex. health status, cigarette
smoking, occupation, income, marital status, medicine usage,
health consciousness, attitude toward risk taking, attitude toward
fate, and attitude toward using medicines.
Part II: The Psychometric Questionnaire
During the past decade, standard questionnaires such as that
used in Part I above have been supplemented by more quantitative
studies in what has come to be known as the psychometric paradigm
9 5for studying risk perception. • J Within this paradigm people
are asked to make quantitative judgments about the riskiness of
various hazards. Perceptions of risk are then related
statistically to quantitative judgments of other properties of the
hazards being studied, such as the degree to which the risks are
known to those persons exposed to them, or the seriousness of harm
in the event of an accident or mishap.
In the present survey, quantitative judgments were made for
each of the 29 items shown in Table 1. These items included 15
pharmaceutical products (e.g., vaccines, antibiotics, etc.), 5
medical devices or procedures (e.g., X-rays, heart surgery), and 9
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medical devices or procedures (e.g., X-rays, heart surgery), and 9
non-medical items (e.g., automobiles, nuclear power) included to
provide a broad context against which to compare and contrast the
medical and pharmaceutical items. The pharmaceutical items were
carefully selected according to several criteria, including
importance, familiarity to the general public, and diversity.
Insert Table 1 about here
Each of the 29 items was rated by each respondent on 7
characteristics of risk similar to those found to be important in
prior studies of perceived risk. In addition to rating the
perceived risk and perceived benefit for each item, respondents
rated the extent to which the risks are known to those exposed to
them, the likelihood that people exposed to the risk would
experience any degree of personal harm, the extent to which the
risk associated with each item was new or old, the seriousness of
harmful effects in the event of an accident or mishap, and the
degree to which a mishap would serve as a warning sign indicating
that the risk from this item might be greater than was thought
before the problem occurred. The full set of rating scales for
S
these seven characteristics is shown in Table 2. All 29 hazard
items were rated on one scale before the next scale was
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considered. Before starting this task, respondents were asked to
examine a glossary which defined each term (e.g., insulin - a drug
used to treat diabetes).
Insert Table 2 about here
A primary contribution of previous risk-perception research
has been to show that qualities of risk such as those surveyed in
the present study determine important societal responses to
hazards. For example, acceptability of risk usually relates
positively to perceived benefit and negatively to perceived risk.
Hazards posing risks that are judged to be new, not well known,
and serious, such as chemical manufacturing or nuclear power, also
tend to be judged most in need of strict governmental regulation.
And when these 'worrisome' technologies experience an accident,
the mishap is likely to be interpreted as a 'warning signal'
(Scale 7) indicating that the responsible company, and perhaps
2
also the industry, is not managing the risks properly. Such
signals may trigger strong societal reactions or 'ripple effects'
(public opposition, liability suits, stricter government
regulation, product withdrawals) that can inflict massive costs on
a company or industry. ' A dramatic example of ripple effects
followed the accident at the Three Mile Island nuclear reactor.
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billions of dollars as a result of reduced output from nuclear
reactors worldwide, costs of using more expensive alternative
8 9fuels, stricter regulation of the industry, etc. ' The Ford
Pinto, the gas tank of which was prone to explode in a collision,
is an obvious example of an extremely serious and costly defect
for the automobile industry, both in terms of the monetary costs
of litigation and intangible losses of good will and public regard
for the manufacturer. The problems that occurred with Thalidomide
provide a similar example of a high-signal event within the
pharmaceutical industry.
The scales included in this survey were selected with the
intent of assessing the potential for costly ripple effects in the
event of mishaps involving specific pharmaceutical products. In
addition, the quantitative judgments of risk and benefit (along
with the imagery data from Part I) can serve as sensitive baseline
data against which to monitor changes in perceptions over time.
Administration of the Survey
A representative sample of the Swedish adult population
between the ages of 16 and 74 was interviewed in their own homes
by personnel from SIFO, a leading survey and market research firm
in Sweden. The interviews took place from February 24 through
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March 19, 1988. From 1234 persons contacted, 961 completed
interviews were obtained, for a completion rate of 78%.
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RESULTS
Characteristics of the Sample
The sample was about equally split between females (50.4%)
and males (49.6%). About 28% of the respondents resided in
Stockholm or Gothenberg; 17% resided in small villages (less than
3000 inhabitants) or rural areas; the remaining 55% came from
towns and cities of intermediate size. Most of the respondents
were between the ages of 16 and 39 (47.3%), 34.8% were between the
ages of 40 and 59, and 17.9% were between 60 and 74 years of age.
In these respects, the sample items closely matched the
characteristics of the Swedish adult population.
The majority of respondents rated their health as either
excellent (34.6%) or very good (28.4%); 30.2% rated their health
as fair and 6.6% as poor. When asked if they had a chronic
illness or condition, 12.7% answered yes; 25.4% said they smoked
more than 5 cigarettes per day.
Some 20.9% of the sample said that they saw their doctor
regularly; 40.2% replied that they had taken prescription drugs
during the past 4 months, and 27.0% had bought a nonprescription
medicine within the previous four months; 62.5% said they had
benefited significantly during the last five years from taking a
prescription drug. As expected, a much higher percentage of the
patients who described themselves as chronically ill had received
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a prescription drug during the past 4 months (68%) than those who
had no chronic illness (37%).
Respondents were asked to indicate the degree to which
various statements about risk taking, health consciousness,
fatalism, and medicine taking described them personally. The
results, shown in Figure 1, indicate that most of these
individuals characterized themselves as not liking to take risks,
being health conscious, not feeling comfortable about taking
medicines, and resisting the use of medicine until they are
absolutely forced to do so (92.2% said they were very or somewhat
well characterized by this last statement). There was more
divergence of views regarding fate. About 38% said they believed
most mishaps in life are predetermined by fate and unavoidable;
61% said that such beliefs did not describe their personal view.
Insert Figure 1 about here
Images of Prescription Drugs
More than 3000 associations were produced in response to the
stimulus concept 'prescription drugs.' The major types of
associations are listed in Table 3 in order of their frequency.
Names of drugs headed the list, followed closely by states and
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names of illnesses and types of drugs. Strong positive images
(helpful, recovery, healing, effective, reliable) accounted for
259 responses. Strong negative imagery was somewhat more frequent
and took two general forms: one form had to do with side effects,
dangerousness, warning, allergic and other reactions, and death
(total frequency of this form, 253); the other had to do with
abuse, addiction, dependency, overdose, and overconsumption (total
frequency, 152). Natural and herbal medicines were mentioned 92
times. Cost was mentioned rather infrequently.
Insert Table 3 about here
Surveys of limited samples of young adults in the United
States have shown that associations to the word 'chemicals' are
dominated by negative imagery (death, toxic, dangerous). The
Swedish data show that responses to one class of chemicals,
prescription drugs, are much more neutral and positive. Overall,
the data in Table 3 seem to provide a useful baseline against
which to compare responses over time in Sweden and responses from
other nations.
Present and Past Risk p
Respondents were asked to indicate whether they believed that
there is more risk, less risk, or about the same risk today than
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there was 20 years ago for each of several types of hazard. The
results, shown in Figure 2, indicate that the risks from chemicals
were perceived to be greater today by 80% of the respondents.
Other percentages for the 'more risk' response were heart disease
(75%), cancer (74%), climate changes (69%), energy sources (67%),
food (62%), quality of drinking water (60%), methods of travel
(54%), infectious diseases excluding AIDS (35%), and prescription
drugs (34%). Looking at the other side of the coin, the
proportion of responses in the 'less risk today' category was
highest for prescription drugs (35.8%) and infectious diseases
(30.4%) and lowest for climate changes (2.7%).
Insert Figure 2 about here
We thus see a strong differentiation in the perceived trend
in risk between prescription drugs and other chemicals as well as
between drugs and other technologies. Although about one-third of
the Swedish sample believes that drug risks have increased, this
is far smaller than the percentage perceiving increased risk from
the other hazards, with the exception of infectious disease, which
may be seen as closely linked to drug efficacy.
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Drug Efficacy and Side Effects
Several questions asked about drug efficacy and the
frequency, severity, and causes of side effects. When asked to
rate the job that various health-care agents were doing to make
sure that prescription drugs are safe and effective, pharmacists
received the highest marks (70% excellent or good), followed at
quite a distance by doctors (56%), government regulatory agencies
(50%) and drug manufacturers (40%), as shown in Figure 3. The
small percentage of excellent ratings for every group suggests
that, in the public mind, there is room for improvement in this
matter.
Insert Figure 3 about here
When asked how often patients taking prescription drugs
experience serious side effects, 23.5% replied always, very often,
or often. When asked whether they personally had suffered a side
effect from taking a prescription drug during the past five years
19.9% replied yes (see Figure 4); of these people, 26.5%
considered the side effect serious. Multiplying these two
proportions indicates that only 5.3% of the total sample claimed
to have suffered a serious side effect, a proportion far smaller
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than that attributed to other patients who take prescription
drugs.
Insert Figure 4 about here
Respondents were also asked to indicate their opinions about
the main cause of a drug side effect. Their spontaneous
responses, shown in Table 4, named patient sensitivity, improper
drug prescription or wrong diagnosis, and non-compliance as the
major causes. Following this question was a structured question
that asked people to indicate how frequently each of eight
specified factors is the cause of a side effect. The results,
shown in Figure 5, indicate that patient sensitivity was again
singled out as one of the most frequent causal factors (44.5%
rated it always, very often, or often a cause). Improper
monitoring of the patient by the doctor was also rated as a
frequent cause (45% always, very often, or often). Slightly less
frequent attributions of causality were assigned to failure to
adequately inform the patient (41%), lack of patient compliance
(38%), and inadequate health and safety testing by the
manufacturer (38%). Again, pharmacist's mistakes were seen as the
least likely causes (2%).
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Insert Figure 5 about here
A Drug Crisis Scenario
The following hypothetical scenario was posed to each
respondent, indicating a possible link between a drug and some
fatalities among its users.
'Imagine that a new prescription drug becomes available in
this country for treating a serious disease. Other drugs are also
available for treating this disease. A study reveals that some
people may have died from taking this drug. What do you think the
government should do in this case?'
-- Leave the drug on the market.
-- Take the drug off the market.
-- Leave the drug on the market but warn the doctors and patients,
- - Not sure.
As Figure 6 indicates, 75% of the respondents wanted the
government to take the drug off the market, 1.8% wanted the drug
left on the market, and another 21.8% wanted it left on the market
with a warning.
Insert Figures 6 and 7 about here
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Those who wanted the drug removed from the market or who were
not sure (76.7% of the total sample) were asked to reconsider
their answers, taking into account each of six possible
extenuating circumstances. The results, shown in Figure 7,
indicated that there is no circumstance that, by itself, would
convince more than 16% of these people to leave the drug on the
market as it was before. However, in combination with information
warning doctors and patients about the possible problem, these
circumstances led to considerable change in opinions. Knowledge
that the risk affected only certain types of patients convinced
5.4% of these respondents to leave the drug on the market and
another 52.6% to leave it on the market with a warning. Changes
such as this also occurred when respondents were told that the
drug is more effective than other, similar drugs, or that the drug
has fewer side effects for most patients than other, similar
drugs. Being told that the drug has been used safely and
effectively for many years in another country produced somewhat
less change of opinions. The two circumstances^that produced the
least opinion change were the fact that the government and
manufacturer are actively gathering more information about the
problem, and the fact that the respondent had taken the drug for
many months and was very satisfied with it.
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Analysis of sample subgroups indicated that those who were
not comfortable taking medicines, those who had suffered side
effects during the past 5 years, those who do not like taking
risks, and those in the younger age groups were most likely to
want the drug withdrawn from the market upon hearing of possible
deaths from taking it. The age factor had the largest effect.
About 76% of respondents age 59 or younger wanted to have the drug
withdrawn after hearing about the study report, while only 66% of
persons in the 60-74 age bracket wanted it withdrawn. In the
second part of the question, older people were much more tolerant
about leaving the drug on the market while the government and
manufacturer gathered more information about the problem. One
exception to this tolerance occurred when the risk of death was
said to affect only certain types of patients, such as elderly
persons with liver problems. In this case only 34.5% and 39.8%,
respectively, of those in the 16-39 and 40-59 age ranges wanted
the drug withdrawn, but 45.2% of those in the oldest age group
wanted it withdrawn, consistent with the suggestion that older
patients were the ones most at risk.
The greater tolerance for risk demonstrated by older persons
on most of the other scenario questions may be due to the fact
that older people are more dependent upon medicines. This, in
turn, suggests that a sample of patients might respond differently
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from our predominantly healthy sample to questions about drug
withdrawals.
The Psychometric Questionnaire
Ratings of each hazard item were averaged across all 961
respondents for each scale. The mean ratings for perceived risk,
ordered from high to low, are shown in Figure 8. Three nondrug
chemicals--cigarette smoking, pesticides, and alcohol--stand out
as highest in perceived risk, followed by two drug items--
antidepressants and sleeping pills--which, surprisingly, are
judged more risky than nuclear power. Vitamin pills, acupuncture,
and herbal medicines were judged lowest in risk.
Insert Figure 8 about here
Analysis of means for specific subgroups of respondents
showed that women perceived far higher risk from nuclear power
than did men (mean rating, 4.86 for women and 3.53 for men; p_ <
.001). This is a common finding in studies of perceived risk.
However, no other differences between men and women exceeded .4.
Those who claimed to have experienced any sort of side effect from
a prescription drug showed slightly higher mean perceptions of
risk than those without side effect experience (the largest mean
difference was .57 for antibiotics; p. < .001). Perceptions of
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risk seemed unaffected by having experienced significant benefits
from taking drugs.
Mean ratings of perceived benefit are shown in Figure 9.
Unlike mean perceptions of risk, which exhibited a smooth,
continuous decline from high to low values, benefits seem to fall
into three categories. High benefits are associated with cancer
drugs, heart surgery, insulin, AIDS drugs, appendectomy,
antibiotics, vaccines, X-rays, airplanes, automobiles, and drugs
to treat arthritis and hypertension. Moderate benefits are
attributed to 11 items ranging from antidepressants to laxatives.
Very low benefits are perceived for cigarettes, alcohol, food
additives, pesticides, artificial sweeteners, and sleeping pills.
The perceived benefit of various drug items was only slightly
higher for those claiming to have experienced significant benefits
in the past 5 years than for those not claiming such beneficial
experiences.
Insert Figure 9 about here
The risk and benefit means are superimposed in Figure 10. It
is obvious that perceived risks and benefits are not positively
related (the correlation is actually -.23). Some items are low
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risk and high benefit (e.g., appendectomy) and others the opposite
(e.g., cigarettes).
Insert Figure 10 about here
Appendectomy, insulin, vaccines, and antibiotics stand out as
being quite high in perceived benefit and low in perceived risk.
Other drug items, with the notable exception of antidepressants
and sleeping pills, show a similar, though less extreme, pattern.
Four nondrug chemical hazards--cigarettes, alcohol, pesticides,
and food additives, were judged extremely high in risk and low in
benefit.
Although the scales are not strictly commensurable, it is
instructive to create a net benefit score by subtracting the risk
judgment from the benefit judgment for each item. Subgroup
analysis on this measure showed that the perceived net benefits
for antidepressants, birth control pills, sleeping pills and
antihypertensives were higher for those persons claiming to be
comfortable taking medicines than for those who are not
comfortable doing so. However, these two groups of people did not
differ in their net benefit ratings for such high benefit drugs as
vaccines, antibiotics, and insulin. Older respondents (ages 60-
74) showed slightly higher net benefit ratings than younger
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respondents for antihypertensives, cancer drugs, antidepressants,
and artificial sweeteners.
Figures 11-15 present the ordered means for the remaining
five scales: likelihood of harm, seriousness of harm, knowledge
of risk among those exposed to it, newness of the risk, and the
strength of the warning signal that would be triggered by a mishap
involving the hazard item. Likelihood of harm (Figure 11) was
almost perfectly correlated with perceived risk (r = .996).
Seriousness ratings (Figure 12) differed from likelihood ratings
in that nuclear power, airplanes, and heart surgery moved to the
highest ranks. Knowledge of risk (Figure 13) took an intermediate
position for all items--there was rather little variation from the
least well known risks (biotechnology drugs, food additives) to
the best known (airplanes, automobiles, and cigarettes). There
was much greater variation on the new vs. old scale (Figure 14)
ranging from AIDS and biotechnology drugs (newest risks) to
cigarettes and alcohol (oldest). The warning sign scale also
showed rather small variation around the midpoint (Figure 15).
Nuclear power and pesticides were highest on this scale, and
automobiles and airplanes were lowest.
Insert Figures 11-15 about here
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Correlation coefficients were calculated between the means of
each pair of scales, across the 29 items. These correlations were
subjected to a principal components factor analysis which
uncovered two dominant, uncorrelated factors accounting for 71% of
the variance in the scales. Factor I, which we shall label
'risk,' consisted of three scales: perceived risk, the likelihood
of harm, and the seriousness of harm, given a mishap. Factor II,
which we shall call 'warning,' consisted of the scales pertaining
to newness, knowledge, and warning sign. Factor scores were
computed for each hazard item by weighting the mean ratings on
each scale proportionally to the importance of that scale for the
factor and summing over all scales. The weighted sum gives each
item a score that is an amalgamation of its ratings on the scales
that define each factor. The factor scores for each item are
plotted in Figure 16. As one moves from left to right in the
factor space, the items are judged to have higher likelihood of
causing harm, greater severity of harm in the event of a mishap,
and, overall, greater perceived risk. As one goes from the bottom
to the top of the space, the items are judged to have risks that
are newer and less precisely known, and a mishap is judged as
providing a stronger warning about the possibility that the risk
is greater than was previously believed.
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Insert Figure 16 about here
As we would expect from the mean ratings shown in Figures 13
(knowledge) and 15 (warning sign), most pharmaceutical products
cluster together at an intermediate level on Factor II. However,
there is great differentiation on the risk factor, with sleeping
pills and antidepressant drugs seen as extremely high in risk.
Nuclear power and pesticides are judged as new, unknown, and high-
risk technologies and are located in the upper-right quadrant of
the space, much as previous studies have shown. Drugs against
AIDS and drugs made by means of biotechnology are seen as new and
unknown risks, and relatively higher in perceived risk than most
other pharmaceutical products.
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DISCUSSION
A prior survey of risk attitudes in Sweden, conducted by SIFO
in January 1988, demonstrated extremely great public concern about
the risks from chemicals. Some 81% of those interviewed agreed
with the statement that 'It can never be too expensive to reduce
the risks from chemicals.' An even stronger anti-chemical
statement--'All use of chemicals must be risk free'--drew
agreement from 75% of the respondents. Such concerns were
exhibited in the present survey in which 80% of the respondents
stated that risks from chemicals are greater today than they were
20 years ago. In addition, chemical items such as food additives
and pesticides were rated extremely high in risk and low in
benefit. Besides being greatly concerned about chemical risks,
the Swedish respondents in the present survey characterized
themselves as persons who disliked taking risks,and who resisted
taking medicines unless forced to do so.
Given these attitudes, we could expect to find rather harsh
views in Sweden about the risks from another class of chemicals--
prescription drugs. For the most part, this was not the case.
Prescription drugs, with the exception of sleeping pills and
antidepressants, were perceived as rather high in benefit and low
in risk. They appeared to be sharply differentiated from other
chemicals and from illicit drugs. The concerns about sleeping
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pills and antidepressants perhaps can be traced to extensive media
publicity in Sweden regarding the risks of addiction and overdose
from these and similar drugs. A subgroup analysis was conducted
in which perceived risks and benefits for those persons (N = 145)
associating prescription drugs with 'overdose,' 'addiction,' or
'abuse' were compared with judgments of persons not having any
negative associations (N = 776). These two groups did not differ
in their ratings of nuclear power, pesticides, and other
nonmedical hazards. Nor did they differ much in their ratings of
vaccines, antibiotics, or cancer drugs. The group with these
negative associations did, however, judge sleeping pills and
antidepressants to have much greater risk and much lower benefits
(p_ < .01) compared to persons without such associations. This
evidence is congruent with the hypothesis that high levels of
perceived risk associated with sleeping pills and antidepressants
stem from concerns about overdose, addiction, and abuse.
Although mishaps involving prescription drugs were judged to
produce only moderate warning signals, the scenario item from Part
I of the survey showed the potential for a strong reaction to a
report of a suspected but not proven link between a drug and some
fatalities. At a hint of trouble in the scenario, 75% of those
surveyed wanted the suspect drug removed from the market.
However, one of the most intriguing findings in this study was the
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indication that evidence of safety and efficacy, in combination
with warning information, could reverse a high proportion of these
initial demands for withdrawal of the drug.
The strategy of marketing a drug to a carefully targeted
patient population, coupled with thorough warnings about its
risks, is currently being pursued by the Alza Corporation in their
marketing of the IUD, Progestasert and by Hoffmann-LaRoche,
Inc. in their marketing of the anti-acne drug Accutane. The
response to the scenario item in the present survey suggests that
appropriate use of warnings may be an important general strategy
for communication with patients about prescription drugs. This
suggestion should certainly be investigated in future studies.
The present study demonstrates the potential usefulness of
survey research for describing and monitoring key attitudes and
perceptions regarding drug risks. Replication of this type of
study in other countries and with samples of patients as well as
with members of the general public should prove valuable.
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Table 1.
Hazard items studied in Part II
1. Pharmaceutical items
Vaccines
Laxatives
Antibiotic Drugs
Birth Control Pills
Insulin
Sleeping Pills
Antihypertensives
Antidepressants
Anticancer Drugs
Aspirin
Herbal Medicines
Vitamin Pills
Antiarthritics
Biotechnology Drugs
Drugs Against AIDS
Medical procedures, tests, and devices
Medical X-rays
IUDs
Nonmedical hazards
Automobiles
Travel by Airplane
Nuclear Power Plants
Pesticides
Heart Surgery
Acupuncture
Appendectomy
Household Cleansers
Artificial Sweeteners
Food Additives
Alcoholic Beverages
Cigarette Smoking
Table 2.
Scales on which the 29 items were rated
RISK TO THOSE EXPOSED
To what extent would you say that people (for instance you or
someone you know) who are exposed to this item are at risk of
experiencing personal harm from it? (1 = they are not at risk; 7
= they are very much at risk)
BENEFITS
In general, how beneficial do you consider this item to be for
society as a whole? (1 = not at all beneficial; 7 = very
beneficial)
LIKELIHOOD OF HARM
How likely would you say it is that people who are exposed to this
item actually will experience any type of personal harm, mild or
serious? (1 = very unlikely to experience harm; 7 = very likely to
experience harm)
SERIOUSNESS OF HARM
If an accident or unfortunate event involving this item occurred,
to what extent are the harmful effects to a person likely to be
mild, or serious? (1 = very mild harm; 7 - very serious harm)
KNOWLEDGE OF THOSE EXPOSED
To what extent would you say that the risks associated with this
item are known precisely to people who are exposed to those risks?
(1 = risk level known; 7 - risk level not known)
OLD OR NEW RISK
To what extent is this item a new risk, or an old one that has
been around for a long time? (1 = very old; 7 = very new)
(Table continues)
Table 2 (continued)
WARNING SIGN
If you read in the newspaper about an accident or an illness
involving this item, in which people were seriously harmed, to
what degree would this mishap serve as a warning sign, indicating
that the risk of this item might be greater than was thought
before the problem occurred? (1 = not a warning sign; 7 = very
strong warning sign)
Table 3
Associations with 'prescription drugs'
Rank Association Count
1 All names of drugs (i.e., valium, etc.) 549
2 All states of illness 465
3 Types of drugs, e.g., antibiotics vitamins 412
4 'Medicine,' i.e., liquid form, syrup 299
5 Pills 261
6 Hospital 258
7 Doctor 222
8 Helpful 188
9 Industry, research, company 161
10 Side effects 136
11 Pharmacy 132
12 Natural, herbal medicine 92
13 Abuse 81
14 Dangerous 78
15 Recovery, healing 60
16 Addiction, dependence 45
17 Prescriptions 42
18 Price, money, cost 33
19 Overdose, overconsumption 26
20 Hypodermic needle 24
21 Bottles, jars, boxes 23
22 Warning 22
23 Profit 21
24 Paraphernalia (general) 18
25 Allergy, reactions 10
26 Preservatives 9
27 Death 7
28 Effective 7
29 Reliable, guaranteed 4
Table 4
Reasons for side effects: spontaneous mentions
Reason Frequency
Patient allergic 33.2%
Wrong drug, diagnosis 27.9%
Noneomp1iance 13.5%
Drug interaction 8.7%
New, untried drug 8.4%
Insufficient control 6.0%
Poor information 5.5%
No answer 5.3%
Basis: n — 1942 spontaneous mentions
FIGURE CAPTIONS
Figure 1. Attitudes toward health, risk, fate, and medicines.
Figure 2. Risk today versus 20 years ago.
Figure 3. Ensuring safety and efficacy: Confidence in selected
health-care groups.
Figure 4. Side-effect experience within the past 5 years.
Figure 5. Reasons for side effects: prompted responses.
Figure 6. Reactions to a drug crisis scenario.
Figure 7. Reactions to a drug crisis: Modification of opinion in
view of additional evidence.
Figure 8. Perceived risk.
Figure 9. Perceived benefit.
Figure 10. Risk and benefit.
Figure 11. Likelihood of harm.
Figure 12. Seriousness of harm.
Figure 13. Knowledge.
Figure 14. Old versus new risks.
Figure 15. Warning signal.
Figure 16. Perceptual map of risk factors.
